Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

Kraft, R; Ansell, Stephen M.; Villasboas, José C.; Bennani, N. Nora; Wang, Yucai; Habermann, Thomas M.; Thanarajasingam, Gita; Lester, Scott C.; Macon, William R.; Inwards, David J.; Porrata, Luis F.; Micallef, Ivana N.; Witzig, Thomas E.; Thompson, Carrie A.; Johnston, Patrick B.; Nowakowski, Grzegorz S.; Lin, Yi; Paludo, Jonas

doi:10.1002/hon.2919

Cited by 14 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…R-CHOP is recognised as the most efficient therapy for PCDLBCL-LT. 1–4 , 7 A French study reported a significant improvement in 3- and 5-year survival rates after treatment with a combination of rituximab and polychemotherapy. 8 …”

Section: Discussionmentioning

confidence: 99%

Germinal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case

Liu¹,

Qi²,

Zhang³

et al. 2022

CCID

View full text Add to dashboard Cite

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) is a rare and the most aggressive type of the cutaneous B-cell lymphoma with poor prognosis and low therapeutic response. It mostly affects elderly women, with a 5-year survival rate of 50% if not efficiently treated. We present a 28-year-old male patient with indolent PCDLBCL-LT who reached nearly 100% clearance after six rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy sessions.

show abstract

Section: Discussionmentioning

confidence: 99%

Germinal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case

Liu¹,

Qi²,

Zhang³

et al. 2022

CCID

View full text Add to dashboard Cite

show abstract

“…PCDLBCL-LT has an intermediate prognosis, with 5-year disease-specific survival of about 60% and an overall survival of about 50% [ 8 ]. Progression-free survival is about 41.8 months in patients treated with chemotherapy and radiotherapy [ 9 ]. Cutaneous dissemination and relapses are common, and systemic dissemination develops in about 17–47% of cases, mainly to lymph nodes.…”

Section: Primary Cutaneous Diffuse Large B-cell Lymphoma Leg Type (Pc...mentioning

confidence: 99%

“…Cutaneous dissemination and relapses are common, and systemic dissemination develops in about 17–47% of cases, mainly to lymph nodes. Adverse prognostic features include multiple lesions, ulceration, CDKN2A inactivation, and MYC rearrangement [ 8 , 9 , 10 , 11 ]. The prognostic role of MYD88 mutation and bcl2 expression is debated.…”

Section: Primary Cutaneous Diffuse Large B-cell Lymphoma Leg Type (Pc...mentioning

confidence: 99%

“…The prognostic role of MYD88 mutation and bcl2 expression is debated. Front-line therapy for PCDLBCL-LT includes R-CHOP with or without involved-site radiation therapy [ 9 ]. Some data suggest that immune checkpoint inhibitors may have a role in the treatment of relapsed/refractory cases [ 9 ].…”

Section: Primary Cutaneous Diffuse Large B-cell Lymphoma Leg Type (Pc...mentioning

confidence: 99%

“…The proliferation index (Ki67) is high—more than 50%. C-myc is expressed in 67–83% of cases [ 9 , 10 , 11 ]. The main pathological findings for diagnostic purpose are summarized in Table 1 .…”

Section: Primary Cutaneous Diffuse Large B-cell Lymphoma Leg Type (Pc...mentioning

confidence: 99%

See 2 more Smart Citations

Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review

Ronchi

Vitiello

D'Abbronzo

et al. 2023

IJMS

View full text Add to dashboard Cite

Most primary cutaneous lymphomas consist of T-cell lymphomas or small cell lymphomas; however, the skin may also be affected by lymphomas with large cell morphology, as a primary or secondary localization. A minority of cases consist of primary cutaneous B-cell lymphomas (PCBCLs). PCBCLs are a heterogeneous group of rare neoplasms with an overlapping morphological and immunohistochemical picture of the different subtypes. Nevertheless, differential diagnosis in the setting of this group of neoplasms is mandatory to identify the correct therapy and prognosis, but it may be challenging since, due to the rarity of these neoplasms, they may not always be familiar to pathologists. Indeed, immunohistochemistry may not be enough to distinguish the different histotypes, which overlap in immunohistochemical features. Furthermore, the ever-increasing knowledge of the molecular features of systemic B-cell lymphomas, such as gene rearrangements with clinical significance, has led in recent years to further investigation into the molecular landscape of PCBCLs with large cell morphology. This work aimed to provide a practical diagnostic guide for pathologists dealing with primary cutaneous large B-cell lymphomas.

show abstract

Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

2023

View full text Add to dashboard Cite

Disease Overview Approximately one‐fourth of primary cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT). Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement. Risk‐Stratification Disease histopathology remains the most important prognostic determinant in primary cutaneous B‐cell lymphomas. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis. Risk‐Adapted Therapy PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.

show abstract

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

Cited by 14 publications

References 20 publications

Germinal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case

Germinal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case

Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review

Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About